Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Benitec Biopharma has disclosed Share-based Compensation across 7 years of filings, most recently posting $7.4 million for Q4 2025.

• Share-based Compensation for Q4 2025 came in at $7.4 million, up 135.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $28.6 million (up 578.05% YoY), and the FY2025 annual result was $17.4 million, up 1999.52% from the prior year.
• Share-based Compensation came in at $7.4 million for Q4 2025 at Benitec Biopharma, up from $5.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.1 million in Q2 2025 to a low of -$48000.0 in Q4 2022.
• The 5-year median for Share-based Compensation is $255000.0 (2021), against an average of $1.7 million.
• Across the five-year window, Share-based Compensation sank 120.08% in 2022 and surged 3274.19% in 2024, its largest moves.
• Benitec Biopharma's Share-based Compensation stood at $239000.0 in 2021, then tumbled by 120.08% to -$48000.0 in 2022, then surged by 293.75% to $93000.0 in 2023, then soared by 3274.19% to $3.1 million in 2024, then surged by 135.15% to $7.4 million in 2025.
• The last three Share-based Compensation figures came in at $7.4 million (Q4 2025), $5.2 million (Q3 2025), and $10.1 million (Q2 2025), per Business Quant data.